EX-4.2





 Exhibit 4.2 

THIS IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE
DEPOSITARY, WHICH MAY BE TREATED BY THE COMPANY, THE TRUSTEE AND ANY AGENT THEREOF AS THE OWNER AND HOLDER OF THIS NOTE FOR ALL PURPOSES. 
 UNLESS THIS
CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY (“DTC”) TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF
CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT HEREON IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DTC), ANY
TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 

TRANSFERS OF THIS GLOBAL NOTE WILL BE LIMITED TO TRANSFERS IN WHOLE, BUT NOT IN PART, TO NOMINEES OF DTC, OR TO A SUCCESSOR THEREOF OR SUCH SUCCESSOR’S
NOMINEE, AND TRANSFERS OF PORTIONS OF THIS GLOBAL NOTE WILL BE LIMITED TO TRANSFERS MADE IN ACCORDANCE WITH THE RESTRICTIONS SET FORTH IN ARTICLE 2 OF THE INDENTURE HEREINAFTER REFERRED TO. 

THE OFFER AND SALE OF THIS NOTE AND THE SHARES OF COMMON STOCK, IF ANY, ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND THIS NOTE MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF OR OF A BENEFICIAL INTEREST HEREIN, THE ACQUIRER:

  

	(1)	 REPRESENTS THAT IT AND ANY ACCOUNT FOR WHICH IT IS ACTING IS A “QUALIFIED INSTITUTIONAL BUYER”
(WITHIN THE MEANING OF RULE 144A UNDER THE SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT; AND 


  

	(2)	 AGREES FOR THE BENEFIT OF THE COMPANY THAT IT WILL NOT OFFER, SELL OR OTHERWISE TRANSFER THIS NOTE OR ANY
BENEFICIAL INTEREST HEREIN, EXCEPT ONLY: 


  

	 	(A)	 TO THE COMPANY OR ANY SUBSIDIARY THEREOF; 



 

	 	(B)	 PURSUANT TO A REGISTRATION STATEMENT THAT HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT; 



 

	 	(C)	 TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE SECURITIES ACT;




  
 1 














	 	(D)	 PURSUANT TO RULE 144 UNDER THE SECURITIES ACT; OR 



 

	 	(E)	 PURSUANT TO ANY OTHER EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT. 


 BEFORE THE REGISTRATION OF ANY SALE OR TRANSFER IN ACCORDANCE WITH (2)(C), (D) OR (E) ABOVE, THE COMPANY, THE
TRUSTEE AND THE REGISTRAR RESERVE THE RIGHT TO REQUIRE THE DELIVERY OF SUCH CERTIFICATES OR OTHER DOCUMENTATION OR EVIDENCE AS THEY MAY REASONABLY REQUIRE IN ORDER TO DETERMINE THAT THE PROPOSED SALE OR TRANSFER IS BEING MADE IN COMPLIANCE WITH THE
SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS.* 
 NO AFFILIATE (AS DEFINED IN RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED) OF THE COMPANY
MAY PURCHASE OR OTHERWISE ACQUIRE THIS NOTE OR ANY BENEFICIAL INTEREST HEREIN. 
  

	*	 This paragraph and the immediately preceding paragraph will be deemed to be removed from the face of this Note
at such time when the Company delivers written notice to the Trustee of such deemed removal pursuant to Section 2.12 of the within-mentioned Indenture. 



  
 2 













 HALOZYME THERAPEUTICS, INC. 

1.25% Convertible Senior Note due 2024 
  

					
	CUSIP No.:	  	40637H AA7†	  	Certificate No. 2024-A1
			
	ISIN No.:	  	US40637HAA77†	  	

 Halozyme Therapeutics, Inc., a Delaware corporation, for value received, promises to pay to Cede &
Co., or its registered assigns, the principal sum of four hundred and sixty million dollars ($460,000,000) (as revised by the attached Schedule of Exchanges of Interests in the Global Note) on December 1, 2024 and to pay interest thereon, as
provided in the Indenture referred to below, until the principal and all accrued and unpaid interest are paid or duly provided for. 
  

	
	 Interest Payment Dates: June 1 and December 1 of each year, commencing on June 1, 2020.

 

	Regular Record Dates:  May 15 and November 15.

 Additional provisions of this Note are set forth on the other side of this Note. 

[The Remainder of This Page Intentionally Left Blank; Signature Page Follows] 

 

	†	 This Note will be deemed to be identified by CUSIP No. 40637H AB5 and ISIN No. US40637HAB50 from and after such
time when the Company delivers, pursuant to Section 2.12 of the within-mentioned Indenture, written notice to the Trustee of the deemed removal of the Restricted Note Legend affixed to this Note. 



  
 3 













 IN WITNESS WHEREOF, Halozyme Therapeutics, Inc. has caused this instrument to be duly
executed as of the date set forth below. 
  

									
		 		 		 	HALOZYME THERAPEUTICS, INC.
					
	Date:	 	November 18, 2019	 		 	By:	 	  

		 		 		 		 	Name:
		 		 		 		 	Title:

 [Signature Page to Global Note 2024-A1] 

 












 TRUSTEE’S CERTIFICATE OF AUTHENTICATION 

The Bank of New York Mellon Trust Company, N.A., as Trustee, certifies that this is one of the Notes referred to in the within-mentioned Indenture. 

 

									
	Date:	 	November 18, 2019	 		 	By:	 	  

		 		 		 		 	Authorized Signatory

 [Certificate of Authentication to Global Note 2024-A1] 












 HALOZYME THERAPEUTICS, INC. 

1.25% Convertible Senior Note due 2024 

This Note is one of a duly authorized issue of notes of Halozyme Therapeutics, Inc., a Delaware corporation (the “Company”),
designated as its 1.25% Convertible Senior Notes due 2024 (the “Notes”), all issued or to be issued pursuant to an indenture, dated as of November 18, 2019 (as the same may be amended from time to time, the
“Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Capitalized terms used in this Note without definition have the respective meanings ascribed to them in the Indenture. 

The Indenture sets forth the rights and obligations of the Company, the Trustee and the Holders and the terms of the Notes. Notwithstanding
anything to the contrary in this Note, to the extent that any provision of this Note conflicts with the provisions of the Indenture, the provisions of the Indenture will control. 

1. Interest. This Note will accrue interest at a rate and in the manner set forth in Section 2.05 of the Indenture. Stated Interest
on this Note will begin to accrue from, and including, November 18, 2019. 
 2. Maturity. This Note will mature on
December 1, 2024, unless earlier repurchased, redeemed or converted. 
 3. Method of Payment. Cash amounts due on this Note will
be paid in the manner set forth in Section 2.04 of the Indenture. 
 4. Persons Deemed Owners. The Holder of this Note will be
treated as the owner of this Note for all purposes. 
 5. Denominations; Transfers and Exchanges. All Notes will be in registered
form, without coupons, in principal amounts equal to any Authorized Denominations. Subject to the terms of the Indenture, the Holder of this Note may transfer or exchange this Note by presenting it to the Registrar and delivering any required
documentation or other materials. 
 6. Right of Holders to Require the Company to Repurchase Notes upon a Fundamental Change. If a
Fundamental Change occurs, then each Holder will have the right to require the Company to repurchase such Holder’s Notes (or any portion thereof in an Authorized Denomination) for cash in the manner, and subject to the terms, set forth in
Section 4.02 of the Indenture. 
 7. Right of the Company to Redeem the Notes. The Company will have the right to redeem the
Notes for cash in the manner, and subject to the terms, set forth in Section 4.03 of the Indenture. 
 8. Conversion. The Holder
of this Note may convert this Note into Conversion Consideration in the manner, and subject to the terms, set forth in Article 5 of the Indenture. 

  
 R-1 













 9. When the Company May Merge, Etc. Article 6 of the Indenture places limited
restrictions on the Company’s ability to be a party to a Business Combination Event. 
 10. Defaults and Remedies. If an Event of
Default occurs, then the principal amount of, and all accrued and unpaid interest on, all of the Notes then outstanding may (and, in certain circumstances, will automatically) become due and payable in the manner, and subject to the terms, set forth
in Article 7 of the Indenture. 
 11. Amendments, Supplements and Waivers. The Company and the Trustee may amend or supplement the
Indenture or the Notes or waive compliance with any provision of the Indenture or the Notes in the manner, and subject to the terms, set forth in Article 8 of the Indenture. 

12. No Personal Liability of Directors, Officers, Employees and Stockholders. No past, present or future director, officer, employee,
incorporator or stockholder of the Company, as such, will have any liability for any obligations of the Company under the Indenture or the Notes or for any claim based on, in respect of, or by reason of, such obligations or their creation. By
accepting any Note, each Holder waives and releases all such liability. Such waiver and release are part of the consideration for the issuance of the Notes. 

13. Authentication. No Note will be valid until it is authenticated by the Trustee. A Note will be deemed to be duly authenticated only
when an authorized signatory of the Trustee (or a duly appointed authenticating agent) manually signs the certificate of authentication of such Note. 

14. Abbreviations. Customary abbreviations may be used in the name of a Holder or its assignee, such as TEN COM (tenants in common), TEN
ENT (tenants by the entireties), JT TEN (joint tenants with right of survivorship and not as tenants in common), CUST (custodian), and U/G/M/A (Uniform Gift to Minors Act). 

15. Governing Law. THIS NOTE, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS NOTE, WILL BE GOVERNED BY AND
CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. 
 *   *   * 

To request a copy of the Indenture, which the Company will provide to any Holder at no charge, please send a written request to the following
address: 
 Halozyme Therapeutics, Inc. 

11388 Sorrento Valley Road 
 San
Diego, California 92121 
 Attention: Chief Financial Officer 

  
 R-2 













 SCHEDULE OF EXCHANGES OF INTERESTS IN THE GLOBAL NOTE 

INITIAL PRINCIPAL AMOUNT OF THIS GLOBAL NOTE: $460,000,000 

The following exchanges, transfers or cancellations of this Global Note have been made: 

 

							
	 Date
	 	 Amount of Increase

(Decrease) in

Principal Amount of

this Global Note
	 	 Principal Amount of

this Global Note

After Such Increase

(Decrease)
	  	 Signature of

Authorized

Signatory of Trustee

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
				
	  
	 	  
	 	  
	  	  

				
		 		 		  	
	  
	 	  
	 	  
	  	  



  
 [Schedule of Exchanges of
Global Note 2024-A1] 













 CONVERSION NOTICE 

HALOZYME THERAPEUTICS, INC. 

1.25% Convertible Senior Notes due 2024 
 Subject
to the terms of the Indenture, by executing and delivering this Conversion Notice, the undersigned Holder of the Note identified below directs the Company to convert (check one): 

☐  the entire principal amount of 

☐  $                     * aggregate principal amount of 
 the Note identified by CUSIP No.
                             and Certificate No.
                        . 

The undersigned acknowledges that if the Conversion Date of a Note to be converted is after a Regular Record Date and before the next Interest Payment Date,
then such Note, when surrendered for conversion, must, in certain circumstances, be accompanied with an amount of cash equal to the interest that would have accrued on such Note to, but excluding, such Interest Payment Date. 

 

							
	Date:                                     
    	 		 	  

		 		 		 	(Legal Name of Holder)
				
		 		 	By:	 	              

		 		 		 	Name:
		 		 		 	Title:
			
		 		 	Signature Guaranteed:
			
		 		 	  

		 		 		 	Participant in a Recognized Signature
		 		 		 	Guarantee Medallion Program
				
		 		 	By:	 	  

		 		 		 	Authorized Signatory

  
  

 

	* 	 Must be an Authorized Denomination. 



  
 [Conversion Notice for
Global Note 2024-A1] 













 FUNDAMENTAL CHANGE REPURCHASE NOTICE 

HALOZYME THERAPEUTICS, INC. 

1.25% Convertible Senior Notes due 2024 
 Subject
to the terms of the Indenture, by executing and delivering this Fundamental Change Repurchase Notice, the undersigned Holder of the Note identified below is exercising its Fundamental Change Repurchase Right with respect to (check one): 

☐  the entire principal amount of 

☐  $                 * aggregate principal amount of 
 the Note identified by CUSIP No.
                                 and Certificate No.
                        . 

The undersigned acknowledges that this Note, duly endorsed for transfer, must be delivered to the Paying Agent before the Fundamental Change Repurchase Price
will be paid. 
  

							
	Date:                                     
	 		 	  

		 		 		 	(Legal Name of Holder)
				
		 		 	By:	 	              

		 		 		 	Name:
		 		 		 	Title:
			
		 		 	Signature Guaranteed:
			
		 		 	  

		 		 		 	Participant in a Recognized Signature
		 		 		 	Guarantee Medallion Program
				
		 		 	By:	 	  

		 		 		 	Authorized Signatory

  

	* 	 Must be an Authorized Denomination. 



  
 [Fundamental Change
Repurchase Notice for Global Note 2024-A1] 













 ASSIGNMENT FORM 

HALOZYME THERAPEUTICS, INC. 

1.25% Convertible Senior Notes due 2024 
 Subject
to the terms of the Indenture, the undersigned Holder of the within Note assigns to: 
  

					
	Name:	 	  
	 	
			
	Address:	 	  
	 	
			
	 Social security or

tax identification number:
	 	  
	 	

 the within Note and all rights thereunder irrevocably appoints: 

as agent to transfer the within Note on the books of the Company. The agent may substitute another to act for him/her. 

 

							
	Date:                                     
        	 		 	  

		 		 		 	(Legal Name of Holder)
				
		 		 	By:	 	              

		 		 		 	Name:
		 		 		 	Title:
			
		 		 	Signature Guaranteed:
			
		 		 	  

		 		 		 	Participant in a Recognized Signature
		 		 		 	Guarantee Medallion Program
				
		 		 	By:	 	  

		 		 		 	Authorized Signatory


  
 [Assignment Form for
Global Note 2024-A1] 













 TRANSFEROR ACKNOWLEDGEMENT 

If the within Note bears a Restricted Note Legend, the undersigned further certifies that (check one): 

 

	1. ☐	 Such Transfer is being made to the Company or a Subsidiary of the Company. 



 

	2. ☐	 Such Transfer is being made pursuant to, and in accordance with, a registration statement that is effective
under the Securities Act at the time of the Transfer. 


  

	3. ☐	 Such Transfer is being made pursuant to, and in accordance with, Rule 144A under the Securities Act, and,
accordingly, the undersigned further certifies that the within Note is being transferred to a Person that the undersigned reasonably believes is purchasing the within Note for its own account, or for one or more accounts with respect to which such
Person exercises sole investment discretion, and such Person and each such account is a “qualified institutional buyer” within the meaning of Rule 144A under the Securities Act in a transaction meeting the requirements of Rule 144A. If
this item is checked, then the transferee must complete and execute the acknowledgment contained on the next page. 


  

	4. ☐	 Such Transfer is being made pursuant to, and in accordance with, any other available exemption from the
registration requirements of the Securities Act (including, if available, the exemption provided by Rule 144 under the Securities Act). 


  

			
	Dated: 	 	  



			
	
	  

		 	(Legal Name of Holder)
		
	By:	 	          

		 	Name:
		 	Title:
	
	Signature Guaranteed:
	
	  

		 	(Participant in a Recognized Signature
		 	Guarantee Medallion Program)
		
	By:	 	              

		 	Authorized Signatory


  
 [Transferor
Acknowledgement for Global Note 2024-A1] 













 TRANSFEREE ACKNOWLEDGEMENT 

The undersigned represents that it is purchasing the within Note for its own account, or for one or more accounts with respect to which the undersigned
exercises sole investment discretion, and that and the undersigned and each such account is a “qualified institutional buyer” within the meaning of Rule 144A under the Securities Act. The undersigned acknowledges that the transferor is
relying, in transferring the within Note on the exemption from the registration and prospectus-delivery requirements of the Securities Act of 1933, as amended, provided by Rule 144A and that the undersigned has received such information regarding
the Company as the undersigned has requested pursuant to Rule 144A. 
  

			
	Dated:	 	  



			
	
	  

		 	(Name of Transferee)
		
	By:	 	              

		 	Name:
		 	Title:


  
 [Transferee
Acknowledgement for Global Note 2024-A1]